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Abstract
Anal fissure is a common problem which can evolve to chronici-
ty. Chronic anal fissure is thought to be an ischemic ulceration
related to sphincter hypertonia. Lateral internal sphincterotomy,
the most common treatment for chronic anal fissure, may cause
permanent injury to anal sphincter leading to fecal incontinence.
To avoid such side effect were developed medications producing a
temporary or reversible sphincterotomy reducing the sphincter
pressure only until the fissure has healed : nitrates, calcium chan-
nel antagonists and botulinum toxin. Authors aimed to summary
the state of research on such treatments (efficacy, side effects,
recurrence risk) and to clarify the role of these different medical
options in the current treatment of chronic anal fissure. (Acta
gastroenterol. belg., 2004, 67, 265-271).
Key words : fissure in ano, nitrates, nitroglycerin, isosorbide dinitrate,
calcium channel blockers, nifedipine, diltiazem, botulinum toxin.
Introduction
Anal fissure is the second proctological affection
after hemorrhoidal disease and the first cause of pain in
proctology. Diagnosis of idiopathic anal fissure is easy,
based on classical clinical triad : longitudinal or ellipti-
cal ulcer at the distal anal canal, nearly always commis-
sural and more often posterior ; spasm of the internal
anal sphincter (IAS) ; characteristic painful syndrome
(pain activated by defecation, followed by a transient
inconstant attenuation of a few minutes and a more
intense secondary recrudescence lasting eventually
hours).
Two stages, acute and chronic, of anal fissure are
described. Acute anal fissures have the appearance of a
superficial tear in the anoderm. Cicatrisation occurs in
up to 45-87% spontaneously or by medical conservative
treatment (stool softeners, bran supplementation, warm
sitz baths and topical anaesthetic solutions) (1-4).
Chronic anal fissures are characterised by thickening of
skin margins and visualisation IAS fibers at its base.
There are frequently accompanied by a sentinel skin tag
at the distal fissure margin and a hypertrophied anal
papilla just proximal to the fissure within the anal canal.
They tend to be refractory to conservative treatment (1).
Physiopathology of anal fissure is multifactorial.
Usually it is thought to be induced by a trauma (passage
of a large/hard stool or diarrhea) but such an initial fac-
tor is not always found. Its posterior commissure loca-
tion is explained by less anatomical resistance and
hypoperfusion of this zone (5). Hypertonia of the inter-
nal anal sphincter is frequently found in chronic fissure
patients (6) and it has been recognised to play a major
role in persistence of fissure by an ischemic mechanism.
Indeed anodermal perfusion depends on arterioles that
must cross the IAS and there is an inverse correlation
between posterior midline anodermal blood flow and
resting anal pressure (7). Increase in anodermal blood
flow has been reported by procedures that normalise
anal resting pressure such as sphincterotomy (8).
The following model resume these different theories.
(Fig. 1) (9). Anal fissure is initially caused by a trauma.
In case of normal anal resting tonus, it heals sponta-
neously or by medical treatment. In case of anal resting
hypertonia, which can be caused by stress or pain, fis-
sure persist and become a chronic ischemic ulceration. 
Discovery of ischemic nature of anal fissure, in close
relation to resting hypertonia, explain efficacy of classi-
cal treatment of chronic anal fissure -surgical treatment-
which mostly consist on lateral internal sphincterotomy
(LIS). Fissure healing under surgery occurs in more than
95% of patients (10-11). However it can also induce fae-
cal incontinence in up to 30% of patients (10-12). Drugs
capable of inducing a reversible relaxing effect on the
IAS have thus been proposed : nitrates, calcium channel
antagonists and botulinum toxin (13-14). This article is
focused to results of this reversible chemical sphinctero-
tomy.
Nitrates
Topical nitrates – mainly glyceryltrinitrate (GTN) but
also isosorbide dinitrate (ISDN) – were the first specific
pharmacological therapy applied topically for chronic
anal fissure. Exogenous nitrates release in vivo nitric
oxide which is the most principal nonadrenergic non-
cholinergic neurotransmitter mediating relaxation of
IAS. In 1994, Loder et al. showed a significant decrease
in resting anal pressure after anal application of GTN
ointment (15). First open studies reported 86-88%
healing rate in chronic anal fissure (16-17). In contrast,
more recent randomised studies showed extremely vari-
ous and often lower healing rates. Results of principal
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randomised trials with topical application of nitrates in
chronic anal fissure are resumed in table 1 (18-34).
Healing rate varied from 30% for worse results to 83-
86% in best ones with a mean of 50-60%. If considering
only randomised versus placebo studies, two important
parameters must be noted. Healing rate has been evalu-
ated to 36-70% in treatment groups but was also very
different in placebo groups (8-52%) (19,22-24,31-32).
These differences could be explained by various defini-
tion used for chronicity of anal fissure : symptom dura-
tion varying from 6 weeks to four months in some stud-
ies (19,21,24,26,30-34), need of sentinel skin tag or
hypertrophied anal papillae presence (24,25,27,34),
exposed IAS fibers (18,24-25,27,30,34), fibrotic fissure
basis or sides (19,22,24-25,30). If acute fissures are inte-
grated as chronic ones in these studies, proportion of fis-
sures which heal spontaneously increases such as heal-
ing rate does both in treatment and placebo groups. This
is likely to cause a reduction in differential healing rate
between active and placebo arms leading to under pow-
ering of the trial. These differences could also be
explained by non standardised nitrates preparations, by
non clearly defined associated conservatives treatments
(warm sitz bath, high-fiber diet, analgesics) and by dif-
ferent treatment duration (4 weeks for Altomare et al.
(24) and 8 weeks for Scholefield et al. (32)). Although
no healing difference was sometimes noted, more rapid
pain relief was sometimes mentioned in nitrate groups
comparing to placebo (23).
Five studies have compared GTN application to LIS
(18,25-27,30) (table 1). LIS was always more effica-
cious than GTN but, save Richard et al. (25), more than
50% of patients healed under topical therapy. These
patients won’t consequently be submitted to potential
incontinence risk of LIS (6.5% reversible minor anal
incontinence for Evans et al. (27) and 3% flatus inconti-
nence for Libertiny et al. (30)).
No incontinence trouble has been reported with topi-
cal nitrates but this treatment induced orthostatic
hypotension, anal burning and especially headaches.
Headaches were present in about 65%, dose-dependent,
more often transitory but sometimes severe (20.5%
(25)), leading to treatment discontinuation in 10%
patients. Headaches constituted a major compliance
problem. Another compliance brake was necessity to
frequent application of topical nitrates (2 or 3 times a
day for 4 to 8 weeks). To avoid this difficulty, Zuberi et
al. tested 10 mg GTN patch (26). Healing rate were
comparable to topical application (63% GTN patch vs.
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Fig. 1. — Physiopathology of Anal Fissure (according de Parades and Parisot)
Table 1. — Main Randomised Trials in Treatment of
Chronic Anal Fissure using Topical Nitrates
Authors Treatment n Healing Rate
(%)
Oettle et al. (18) GTN 1.5 mg tid 24 83
vs. LIS 100
Lund et al. (19) 0.2% GTN 80 68
vs. Placebo 8
Bacher et al. (20) 0.2% GTN 13 63
vs. Lidocaine 20
Brisinda et al. (21) 0.2% GTN 50 60 
vs. BT 20 U 96
Carapeti et al. (22) 0.2% to 0.6% GTN 70 65 to 70
vs. Placebo 32
Kennedy et al. (23) 0.2% GTN 43 46
vs. Placebo 16
Altomare et al. (24) 0.2% GTN 119 49
vs. Placebo 52
Richard et al. (25) 0.25% GTN 82 30
vs. LIS 90
Zuberi et al. (26) 0.2% GTN 49 67
vs GTN 10 mg patch 63
vs. LIS 92
Evans et al. (27) 0.2% GTN 65 61
vs. LIS 97
Werre et al. (28) 1% ISDN 37 85
vs. Placebo 35
Kocher et al. (29) 0.2% GTN 60 86
vs. 2% Diltiazem 77
Libertiny et al. (30) 0.2% GTN 70 54
vs. LIS 100 
Bailey et al. (31) 0.1 to 0.4% GTN 304 50
vs. Placebo 50
Scholefield et al. (32) 0.1 to 0.4%¨GTN 200 36 to 57
vs. Placebo 24
Bielecki et al. (33) 0.5% GTN 43 86
vs. 2% Diltiazem 86
Ezri et al. (34) 0.2% GTN 52 58
vs. 0.2% Nifedipine 89
(GTN, glyceryl trinitrate ; LIS, lateral internal sphincterotomy ; BT,
botulinum toxin ; ISDN, isosorbide dinitrate).
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67% topical GTN) with similar headache side effects.
Other important problems were tachyphylaxis which
reduced treatment efficacy (35) and, above all recurrence
risk. Recurrence rate varied from 16 to 46% depending
on studies and follow-up duration (24,26-27,32,36-39).
Some studies were especially designed to fissure
recurrence in GTN healed patients. Lund et al. (36)
showed 27% fissure recurrence rate at 28 months while
Lysy et al. (37), Jonas et al. (38) and Libertiny et al. (30)
showed 21% at 11 months, 27% at 6 months and 16% at
24 months respectively. In these studies 0 to 8.6% of
GTN-healed patients were at last treated by LIS for 
fissure recurrence, all others being treated again by 
GTN ointment with success or spontaneously healed.
Recurrence of fissure after healing has been associated
with the presence of a sentinel pile (38,39). At last
Christie et al. calculated that a nitroglycerin ointment 
is a cost-effective first-line treatment strategy for the 
management of anal fissure (40).
Calcium Channel Antagonists
Because calcium is important for smooth muscle con-
traction, calcium channel antagonists have also been
evaluated for anal fissure treatment. Nifedipine and dil-
tiazem have been used topically or orally in this indica-
tion. Manometric studies established reduction of anal
pressure on nifedipine or diltiazem therapy (41-43). In
acute anal fissure, Antropoli et al. showed, in a cohort of
283 patients, superiority of topical 0.2% nifedipine oint-
ment on association 1% lidocaïne / 1% hydrocortisone
(95% vs. 50% healing rate respectively) (44). Main tri-
als on calcium channel antagonists in treatment of
chronic anal fissure are shown on table 2 (29,33-34,42-
43,45-50). Cook et al. observed healing in nine of
15 patients (60%) after 8 week of therapy with oral
nifedipine (2  20 mg) (42). Two randomised studies on
topical nifedipine showed good results with respectively
89% and 95% healing rate (34,45). Oral nifedipine
seemed to be less efficacious (42). Studies on topical dil-
tiazem ointment are more numerous : five
open (43,46,48-50) and 3 randomised (29,33,47) studies
(one vs. oral diltiazem and 2 vs. GTN ointment).
Elevated healing rate were confirmed in most studies
with topical diltiazem. DasGupta et al., Jonas et al. and
Griffin et al. reported less efficacy with respectively
48%, 49% and 47% healing rate (48-50). But, in these
open trials, studied populations were partially (48) or
totally (49-50) patients who failed to heal on GTN oint-
ment. Randomised trials on topical diltiazem showed 65
to 86% healing rate, roughly as effective as GTN treat-
ment (29,33,47). Oral diltiazem seemed less efficacious
than topical application (38% vs. 65% healing rate) (47).
Major advantage of calcium channel antagonists on
nitrates is best tolerance. In topical use, side effects
mainly consisted on local hyperhemia (2 to
10%) (29,46,48). Headaches were less frequent, from 5
to 26%, even in randomised studies compared to GTN
ointment (29,33). In oral use, tolerance was poorer with
rash, headaches, nausea or vomiting (46). Recurrence
rate is still not really known (4 to 17% at 6 months
follow-up (46-47)) because long term studies are lack-
ing. Until now there are no comparative studies with
placebo or surgery. Despite these promising results,
however, no commercially or commonly accepted
magistral preparation with calcium channel antagonists
are available in our country. 
Botulinum Toxin
Locally injected botulinum toxin (BT) has been used
as an alternative approach to sphincter relaxation in the
treatment of anal fissure. BT is a neurotoxin which pre-
vents acetylcholine release from presynaptic nerve ter-
minals and inhibits neuromuscular transmission in stri-
ated muscles. It leads to smooth muscle relaxation by a
not clearly yet known mechanism. Interest of BT is
reversible action by new nerve terminals regrowth in a
few months, thus preserving sphincter from definitive
lesions. BT is commercially available on two forms :
Botox° (Allergan) and Dysport° (Ipsen Pharma). These
two forms are not dose equivalent : one labelled unit of
Botox° is thought to be equivalent to 3-4 labelled units
of Dysport (51-52). Most studies were made with
Botox°. All later BT dose in the text will be in Botox°
unit in absence of contrary mention. Two different tech-
niques have been described with injection location either
in external anal sphincter (EAS) or in IAS. Jost and
Schimrigk first reported the use of BT injection in EAS
for anal fissure in 1993 (53). This injection location has
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Table 2. — Main Trials in Treatment of Chronic Anal
Fissure with Calcium Channel Antagonists
Author Treatment n Healing Rate
Cook et al. (42) Nifedipine 20 mg po bid 15 60%
Perrotti et al. (45) Top 0.3% Nifedipine / 110 95%
1.5% Lid
vs. top 1.5% Lid/1% HC 17%
Ezri et al. (34) Top 0.2% Nifedipine 52 89%
vs. top 0.2% GTN 58%
Carapeti et al. (43) Top 2% Diltiazem 30 67%
Knight et al. (46) Top 2% Diltiazem 71 75%
Jonas et al. (47)* Top 2% Diltiazem 50 68%
vs. Diltiazem 60 mg 38%
po bid
DasGupta et al. (48) Top 2% Diltiazem 23 48%
Kocher et al. (29)* Top 2% Diltiazem 60 77%
vs. top 0.2% GTN 86%
Jonas et al. (49) Top 2% Diltiazem 39 49%
Griffin et al. (50) Top 2% Diltiazem 47 47%
Bielecki et al. (33)* Top 2% Diltiazem 33 86%
vs. top 0.5% GTN 86%
(po, by mouth ; bid, twice daily ; Top, topical ; Lid, lidocaine ;
HC, hydrocortisone ; GTN, glyceryl trinitrate ; *randomised trial).
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been chosen by two research teams exclusively in open
studies (53-57). No clear manometric measures were
systematically done but decrease in resting pressure was
described, explained either by direct action on EAS or
by diffusion in IAS. These open studies showed healing
rate of 78-85% with 5-20 U Botox° (53-54,57) or 20-40
U Dysport° (55) injection. On the other hand, in IAS
injection, manometric measures showed significant
decrease of resting anal pressure by 18-30% with minor
or no modification of squeeze pressures (21, 58-65).
Open studies reported healing rate of 67-100% with 10-
40 U BT injection (58,60,62,66). Main randomised trials
of BT injection in IAS for treatment of chronic anal fis-
sures are shown in table 3 (21,61,63-65,67-69). These
studies confirmed healing rate of 71-96% save
Siproudhis et al. whose injection in IAS was unilateral
in contrast to others (bilateral injection). Maria et al.
conducted a double-blind, placebo-controlled trial of BT
injection on either side of the fissure vs. saline in
30 chronic anal fissure patients (61). Healing occurred in
73% of treated patients at 2 months (vs. 13% in control
group). The 4 unhealed patients in the BT arm under-
went second injection (rescue therapy) and all healed
within 2 months. Other authors have latest confirmed
that rescue therapy after failure at 2 months was safe and
efficacious either with the same dose (61,68) or with a
slightly higher dose (25 U instead of 20 U (63) ; 50 U
instead of 50 U (64)). Another trial by Maria et al. inves-
tigated the influence of the site of injection on healing
rate (63). In this randomised, double-blind study,
authors injected, in the IAS, a total of 20 U BT either on
each side of the posterior midline or on each side of the
anterior midline. Anterior midline injection seemed
more efficacious with a healing rate of 100% with 12%
retreated patients in contrast with 80% healing rate with
25% retreated patients in posterior midline injection.
This could be explained by marked fibrosis at the base
of the fissure reducing IAS compliance and BT diffu-
sion. Optimal dose to use is difficult to determinate
because studies were made with different dosages.
Minguez et al. studied three doses : 10, 15 and 21 U with
healing rate of 83%, 81% and 95% and necessity of two
injections in 52%, 30% and 37% of patients respective-
ly (62). Brisinda investigated two doses : 20 and 30 U
with 100% healing rate in both groups and a second
injection in 11% and 4% of patients respectively (64).
However in 30 U group, 3% of patients experienced
transitory gas anal incontinence. 20 U injection could
consequently be optimal dose even though injections
were not identically realised in these two studies.
Brisinda et al. injected on each side of the anterior mid-
line of IAS while Minguez et al. injected “through the
intersphincteric groove in the direction of the internal
sphincter” on each side of anal canal (10-unit group),
with a third aliquot injected into the IAS immediately
below the fissure in 15-unit and 21-unit groups. 
BT has been compared both to nitrate therapy and to
surgical treatment. Brisinda et al. demonstrated superior
efficacy of BT injection on topical nitrates (96% vs.
60% healing rate respectively) and showed less side
effects in BT group (0% vs. 20% – headaches – in GTN
group) (21). In this study there was no anal incontinence
nor fissure recurrence at 15 months. Combined therapy
by BT and topical nitrates (DNI) was not more effica-
cious even though healing was more rapid (67).
Compared to LIS, healing was less frequent in BT group
(96% in LIS group vs. 74% at 2 months and 87% at
8 months with 16% second injection in BT group) (68).
However there were no side effects in BT group while
16% transitory anal incontinence was noted in LIS
group. Full return to daily activities took also signifi-
cantly less time in BT group (1 vs. 15 days in LIS
group). A first-line topical nitrate treatment followed by
BT injection in case of failure could allow to avoid
surgery in 80 to 85% patients (70).
Complications of BT treatment are not very frequent.
Reported side effects were < 1% haemorrhoid prolapse
or self-limited subcutaneous infection ; < 3% anal
haematoma, haemorrhoidal thrombosis, flu-like syn-
drome or transient faeces incontinence, 3 to 16% tran-
sient flatus incontinence (54-55,62,64,67,68,71). Recur-
rence rate is usually estimated to 0 to 12% depending on
duration follow-up (21,54-56,60-61,63-64,68). Minguez
et al. recently reported higher recurrence rate of 41.5%
at 42 months (72). Risk factors for recurrence were ante-
rior location of fissure, longer duration of the disease,
need for reinjection, high dose to achieve healing and
lower decrease of maximum squeeze pressure. Main
problem of BT use is cost. Botox° is available on 100-
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Table 3. — Main Randomised Trials in Treatment of
Chronic Anal Fissure using Botulinum Toxin Injection.
All injections were made in the IAS (internal anal sphinc-
ter). All botulinum toxin injections were made with
Botox° except one (BT) with Dysport°
Author Treatment n Healing Rate
Maria et al. (61) BT 20 U 45 73% (100%*)
vs. placebo 13%
Brisinda et al. (21) BT 20 U 50 96%
vs. topical 0.2% GTN 60%
Maria et al. (63) BT 20 U ant 50 60% (80%*)
vs. BT 20 U post 80% (100%*)
Lysy et al. (67) BT 20 U 73%
vs. BT 20 U / 30 66%
2.5 mg ISDN
Brisinda et al. (64) BT 20 U 150 89% (100%*)
vs. BT 30 U 96% (100%*)
Colak et al. (65) BT 50 U 62 71%
vs. topical Lidocaine 22%
Mentes et al. (68) BT 0.3 U/kg 111 74% (87%*)
vs. LIS 96%
Siproudhis et al. (69) BT 100 U 44 23%
vs. placebo 50%
(BT, botulinum toxin ; GTN, glyceryl trinitrate ; ant, anterior mid-
line injection ; post, posterior midline injection ; ISDN, isosorbide
dinitrate ; LIS, lateral internal sphincterotomy ; * = with second injec-
tion).
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unit vial at a cost of nearly 220 € and Dysport ° on 500-
unit vial at a cost of nearly 250 €, that is to say a patient-
cost of about 40-42 €, on a 80 U-Dysport or 20 U-Botox
basis, if you find 5-6 patients to treat the same day ! 
Conclusion
There is no proven optimal treatment for anal fissure
(73). Different options with their merits and disadvan-
tages must be examined with patient. Proposed algo-
rithm fissure treatment is shown in fig. 2. In practice,
topical treatment can always be tried. Ideal topical ther-
apy could be calcium channel antagonist but, in the
absence of adequate ointment formula, topical treatment
is at present based on nitrates. In case of failure, choice
between BT injection and surgery exists with a prefer-
ence to BT injection in case of sphincter risk factors. A
first-line BT injection therapy could also be discussed. It
is limited by price and current availability of BT.
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